Currently, there are 47.83M common shares owned by the public and among those 44.92M shares have been available to trade.
The company’s stock has a 5-day price change of -5.49% and 18.18% over the past three months. QURE shares are trading -13.59% year to date (YTD), with the 12-month market performance down to -32.99% lower. It has a 12-month low price of $3.73 and touched a high of $11.35 over the same period. QURE has an average intraday trading volume of 2.84 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -13.85%, -12.77%, and -1.66% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of uniQure N.V. (NASDAQ: QURE) shares accounts for 65.32% of the company’s 47.83M shares outstanding.
It has a market capitalization of $284.89M and a beta (3y monthly) value of 0.96. The earnings-per-share (ttm) stands at -$5.92. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.32% over the week and 6.37% over the month.
Earnings per share for the fiscal year are expected to increase by 32.79%, and 29.98% over the next financial year.
Looking at the support for the QURE, a number of firms have released research notes about the stock. Goldman stated their Neutral rating for the stock in a research note on February 29, 2024, with the firm’s price target at $8. Mizuho coverage for the uniQure N.V. (QURE) stock in a research note released on December 19, 2023 offered a Neutral rating with a price target of $10. UBS was of a view on March 17, 2022 that the stock is Buy, while BTIG Research gave the stock Buy rating on June 15, 2021, issuing a price target of $46. UBS on their part issued Neutral rating on May 21, 2021.
